Sakar Healthcare (SAKAR) Q2 FY27 Profit Soars 149% as Oncology Exports Ramp Up
The pharma company's Q2 profit more than doubled on strong revenue growth, though a sequential margin dip hints at the cost of scaling up.
Sakar Healthcare's Q2 FY27 profit surged 149% year-on-year to ₹11.31 crore, driven by a 52% jump in revenue. The growth is fueled by its expanding oncology export business and new regulatory approvals.
For Sakar Healthcare, the story is now about turning a pipeline of regulatory approvals into commercial shipments. The second quarter shows that transition accelerating, with revenue surging past expectations and profit more than doubling from a year ago.
The numbers tell a story of powerful growth, albeit with a sequential efficiency check. Revenue hit ₹87.42 crore, up 51.9% from a year ago and 19.8% from the prior quarter. Profit followed sharply higher, rising 149.1% year-on-year to ₹11.31 crore. The year-on-year net profit margin expanded by 500 basis points to 12.9%, though it eased from 14.1% in Q1.
Revenue (₹ Cr)
Profit (₹ Cr)
Net Profit Margin
| Metric | CurrentQ2 FY27 | PreviousQ1 FY27 | Same quarter LYQ2 FY26 |
|---|---|---|---|
| Revenue (₹ Cr) | 87.42YoY +52% | 72.97 | 57.56 |
| Profit (₹ Cr) | 11.31YoY +149% | 10.29 | 4.54 |
| Net Profit Margin | 12.9%YoY +63% | 14.1% | 7.9% |
The Export Engine Fires Up
The explosive growth is rooted in Sakar's strategic pivot to oncology exports. According to reports from Stockfin.ai and SAHI, the company is leveraging its EU GMP-certified facility and a growing list of marketing authorizations. Management had previously guided that exports, which contributed just ₹6.5 crore in Q1, would need to ramp up to hit a ₹90 crore quarterly revenue run rate. Q2's ₹87.42 crore top-line suggests that process is underway, driven by commercial dispatches to partners like Accord and Torrent in regulated markets.
Why Margins Took a Sequential Step Back
Despite the revenue leap, net profit margin dipped 120 basis points from the previous quarter. This points to the costs of commercializing new approvals and scaling operations. Reports indicate the company is in a phase of heavy commercial investment, with initial dispatches facing 'teething problems' in logistics and serialization. Furthermore, the revenue mix may have shifted slightly, as higher-margin export sales are still building alongside the established domestic contract manufacturing business.
Guidance Points to Sustained Momentum
The outlook remains firmly growth-oriented. Management, cited by Tradebrains, is targeting oncology revenue of roughly ₹200 crore for FY27, nearly double the prior year's level, with a further jump to ₹280-300 crore planned for FY28. A key lever will be backward integration; using more of its own APIs in finished drugs is expected to lift EBITDA margins toward 35% for select products. The company has stated that major capacity expansion capex is largely complete, allowing operating leverage to build from here.
Live Chart
· SAKAR
(BSE)
ISIN: INE732S01012
Key Points
- Sakar Healthcare's Q2 FY27 revenue grew 51.9% year-on-year to ₹87.42 crore, while profit surged 149.1% to ₹11.31 crore.
- The growth is primarily driven by the ramp-up of oncology exports from its EU GMP facility and new marketing authorizations.
- Net profit margin improved significantly year-on-year but softened sequentially, reflecting commercialization costs and a shifting business mix.
- Management guidance projects oncology revenue to nearly double this fiscal year, with further gains expected from higher-margin, backward-integrated products.
Hexa Perspective
The quarter confirms Sakar Healthcare is successfully executing its pivot from a domestic-focused manufacturer to an export-led oncology player. The sequential margin compression is not alarming; it's the typical friction of scaling a new, complex business line. The critical factor for the next few quarters is the conversion rate of its substantial pipeline of over 178 submitted dossiers into commercial sales. If export contribution continues to rise as guided, the company's margin structure should improve, moving it closer to its 30%+ EBITDA margin target. The current valuation, at a discount to the industry PE, appears to be weighing the execution risk against this visible growth runway.
Also read
Want this applied to your portfolio?
Talk to a HexaWealth advisor, or sync your mutual fund data for insights tailored to your holdings.